Age \>=18 years, either sex, any race.

Subjects must have histologically proven solid tumors, non-Hodgkin's lymphoma, or multiple myeloma.

There must be no known standard therapy, or disease must be refractory to standard therapy.

Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

Adequate hematologic, renal, and hepatic organ function and laboratory parameters.

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)